Solid Biosciences stockholders elect four Class II directors, ratify auditor, approve ESPP amendment

Solid Biosciences Inc.

Elected Clare Kahn, Adam Koppel, Adam Stone, Lynne Sullivan as Class II directors to 2026; votes ranged 13.6M–14.2M for, 76K–664K withheld.
Ratified PricewaterhouseCoopers LLP as auditor for FY 2023 with 15.3M for, 4.9K against, 5.5K abstain.
Approved amendment to 2021 ESPP increasing shares available for issuance; 13.6M for, 679K against, 4K abstain.
All results from June 6, 2023 Annual Meeting; broker non-votes of ~1.1M on director election and ESPP amendment.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Solid Biosciences Inc. shareholders approved Election of Class II directors at the 2023-06-06 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

The Company held its Annual Meeting on June 6, 2023 to consider and vote upon the matters listed below.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Solid Biosciences Inc. shareholders approved Amendment to the Company's 2021 Employee Stock Purchase Plan to increase number of shares available for issuance at the 2023-06-06 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

The Company’s stockholders approved an amendment to the Company’s 2021 Employee Stock Purchase Plan to increase the number of shares available for issuance thereunder.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Solid Biosciences Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Browse all shareholder votes →

Solid Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-164486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.